Abstract 138P
Background
Generation of specific and durable T cell response is the basis of antigen targeted cancer vaccine strategies. A study in healthy male subjects conducted over a one-year period investigated the generation of antigen specific T cell responses from a peptide vaccine FMPV-1, targeting frameshift mutated (mut) transforming growth factor receptor 2 (TGFβR2), commonly occurring in cancers with microsatellite instability (MSI-H). Granulocyte macrophage colony stimulating factor (GM-CSF) was used as adjuvant.
Methods
An open label study was conducted in 16 healthy male subjects who received intradermal FMPV-1 (0.15 mg/injection) preceded by GM-CSF (0.03mg/injection) on Days 1, 8, 16, 29 and 43. Immune responses were assessed by in vivo delayed type hypersensitivity (DTH) in all subjects on Days 1, 29 and 43 and in 7 subjects after 6 months, and in vitro assessment of induced FMPV-1 antigen specific T cells at Days 1, 57, 80, 6 months and 12 months, with Stimulation Index (SI) values ≥ 2 considered positive. Plasma samples were assayed for the presence of mut (A9) TGFβR2 circulating cell-free DNA (cfDNA) fragments and wildtype (wt) (A10) TGFβR2 cfDNA fragments. Subjects were assessed for safety and tolerability.
Results
None of the 16 subjects had a positive DTH before vaccination. After 3 and 4 vaccinations, 8/16 and 15/16 subjects had a positive DTH response respectively. At 6 months 5/7 subjects still had a positive DTH response. FMPV-1 antigen-specific T cells were detected shortly after the vaccination period and at 6 and 12 months. Neither mut nor wt TGFβR2 cfDNA fragments were detected in any subject. Vaccination with FMPV-1/GM-CSF was well tolerated out to 1 year following initial dosing.
Conclusions
The FMPV-1 peptide vaccine is immunogenic and induces frameshift mutant TGFβR2 specific T cells after a short vaccination period in healthy subjects. This provides a rationale for FMPV-1 treatment of MSI-H cancer patients in combination with immune checkpoint inhibitors. With the favourable safety profile and ability to induce frameshift mut TGFβR2 specific memory T cells, FMPV-1/GM-CSF may play an important role in both therapeutic and prophylactic settings of cancer.
Clinical trial identification
EudraCT 2020-004363-80.
Legal entity responsible for the study
Quotient Sciences.
Funding
Hubro Therapeutics AS.
Disclosure
S.J. Arbe-Barnes: Financial Interests, Personal, Full or part-time Employment: Hubro Therapeutics AS. J.A. Eriksen: Financial Interests, Personal and Institutional, Stocks/Shares: Hubro Therapeutics AS; Financial Interests, Personal, Officer: Hubro Therapeutics AS. B. Iverson, H. Kvalheim, R.M. Miller, K. Risberg Handeland: Financial Interests, Institutional, Full or part-time Employment: Hubro Therapeutics AS. N. Singh: Other, Institutional, Local PI: Quotient Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display